Investor Presentation First Nine Months of 2022
134
Investor presentation First nine months of 2022
North America Operations at a glance
NAO
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
DKK
billion
First nine months
of 2022
Sales
(mDKK)
Growth²
70
10%
800
80%
Total GLP-13
40,133
39%
60
11%
Long-acting insulin4
4,122
-27%
50
600
60%
Premix insulin5
364
-26%
38.2%¹
Fast-acting insulin
4,701
-16%
40
GLP-1
Human insulin
1,249
-6%
400
40%
30
63
Total insulin
10,436
-20%
57
51
Insulin
1.6%1
Other Diabetes care?
599
-26%
20
20
200
20%
Diabetes care
51,168
20%
10
14.5%1
OAD
Obesity care
7,235
77%
0
2021
0
0%
Diabetes & Obesity
2030
2045
Aug
2017
Aug
2022
58,403
25%
care
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
OAD MS
Rare disease⁹
Total
6,044
-3%
64,447
22%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Aug 2022: Novo
Nordisk 42%, Eli Lilly 30% and Sanofi 27%; Competitor GLP-1
value market shares, as of Aug 2022: Novo Nordisk 53%, Eli Lilly
44% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
Aug 2022 value figures
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises NovoMix®;
6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and WegovyⓇ9 Comprises primarily NovoSevenⓇ,
Novo Eight® Esperoct®, NovoThirteen®, Refixia®, Norditropin®, VagifemⓇ and
Activelle®View entire presentation